)
Nikhil Thatte
Partner
Lumira Ventures
Nikhil Thatte is a Partner with Lumira Ventures and been with the firm since March 2019. Nikhil leads Lumira’s investment efforts in next generation modalities including protein degradation, gene therapy, cell therapy, and gene editing and represents Lumira Ventures as a board member or observer at a number of its portfolio companies including Specific Biologics (gene editing, Toronto), COUR Pharmaceuticals (antigen-specific tolerance, Chicago), BioTheryX (protein degradation, San Diego) and XyloCor Therapeutics (cardiovascular gene therapy, Philadelphia). He also co-led Lumira’s investment and successful exit in ESSA Pharma (prostate cancer, Vancouver) which achieved a 3x return in less than 6 months. Prior to Lumira Ventures, Nikhil worked as a Director with DRI Capital as a member of the business development and investment teams and as a Consultant with ZS Associates, where he provided sales and marketing expertise to nearly all top 10 pharmaceutical companies across a broad range of projects and therapeutic areas. Nikhil also served as an Analyst with Bayer AG and Health Canada, and holds a Bachelor’s Degree in Chemical Engineering from McGill University in Montréal.
Sessions
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}